← Leaderboards
John Varga
University Of Illinois At Chicago
$15,528,672
Attributed
$17,078,831
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,078,831 · 15
By mechanism
R01$12,340,342 · 4
R21$2,077,050 · 6
R56$996,675 · 2
P30$734,004 · 1
R61$589,662 · 1
R33$341,098 · 1
Top collaborators
- Eduardo N Chini5 shared
- John Patterson Atkinson2 shared
- Stephen D Miller2 shared
Others in their field
Top investigators on “Scleroderma”
- Eugene W. St Clair · Duke University$24,182,181
- Maria Trojanowska · Boston University Medical Campus$15,165,208
- Roger A Johns · Johns Hopkins University$12,479,815
- Carol A Feghali-Bostwick · University Of Pittsburgh At Pittsburgh$12,032,767
- Judith A James · Oklahoma Medical Research Foundation$11,331,322
- Robert M Elashoff · John Wayne Cancer Institute$10,394,671
Research focus
SclerodermaFibrosisFibroblastsSkinSystemic SclerodermaResponsePathogenesisBiopsyOrganPathway InteractionsLinkBaseInflammationTissuesMediatingEffective TherapyCellsIn VitroMyofibroblastCollagenSignal TransductionMouse ModelIn VivoInsight
Grant awards (58)
CD38 modulation of NAD metabolism driving scleroderma pathogenesis$601,753
R01 · FY2025 · AR · contact PI
CD38 modulation of NAD metabolism driving scleroderma pathogenesis$648,599
R01 · FY2024 · AR · contact PI
CD38 modulation of NAD metabolism driving scleroderma pathogenesis$682,658
R01 · FY2023 · AR · contact PI
Damage-Associated Molecular Patterns Driving Fibrosis Progression in Scleroderma$412,063
R01 · FY2023 · AR · contact PI
Damage-Associated Molecular Patterns Driving Fibrosis Progression in Scleroderma$445,133
R01 · FY2022 · AR · contact PI
Metaorganismal TMAO pathway driving scleroderma pathogenesis: novel gene-environment interaction paradigm and therapeutic target$341,098
R33 · FY2022 · AR · contact PI
Damage-Associated Molecular Patterns Driving Fibrosis Progression in Scleroderma$463,297
R01 · FY2021 · AR · contact PI
Metaorganismal TMAO pathway driving scleroderma pathogenesis: novel gene-environment interaction paradigm and therapeutic target$233,600
R61 · FY2021 · AR · contact PI
Scleroderma Renal Crisis as a Genetic Complementopathy$168,302
R21 · FY2021 · AR
Damage-Associated Molecular Patterns Driving Fibrosis Progression in Scleroderma$490,351
R01 · FY2020 · AR · contact PI
Scleroderma Renal Crisis as a Genetic Complementopathy$220,734
R21 · FY2020 · AR
Damage-Associated Molecular Patterns Driving Fibrosis Progression in Scleroderma$517,829
R01 · FY2019 · AR · contact PI
Metaorganismal TMAO pathway driving scleroderma pathogenesis: novel gene-environment interaction paradigm and therapeutic target$356,062
R61 · FY2019 · AR · contact PI
Novel Role for A20 in Fibrosis Susceptibility$208,560
R21 · FY2019 · AR · contact PI
Targeting NAD metabolism to treat systemic sclerosis$174,240
R21 · FY2019 · AR · contact PI
Regulation of the Profibrotic Mechanisms of MACRO+ Myeloid Cells in Scleroderma$173,800
R21 · FY2019 · AR
Aberrant TLR responses driving organ fibrosis in systemic sclerosis$477,095
R56 · FY2018 · AR · contact PI
Targeting NAD metabolism to treat systemic sclerosis$221,672
R21 · FY2018 · AR · contact PI
Regulation of the Profibrotic Mechanisms of MACRO+ Myeloid Cells in Scleroderma$208,560
R21 · FY2018 · AR
Novel Role for A20 in Fibrosis Susceptibility$173,800
R21 · FY2018 · AR · contact PI
Sirtuins: novel determinants and therapeutic target in systemic sclerosis$519,580
R56 · FY2016 · AG · contact PI
Core D - Proteomic and Clinical Core$139,784
P30 · FY2015 · AR · contact PI
Molecular Basis of Fibrosis: Regulation of Collagen$322,812
R01 · FY2014 · AR · contact PI
Targeting Adiponectin Signaling: Novel Peptide Therapy for Scleroderma$163,991
R21 · FY2014 · AR · contact PI
Core D - Proteomic and Clinical Core$141,954
P30 · FY2014 · AR · contact PI
Molecular Basis of Fibrosis: Regulation of Collagen$312,930
R01 · FY2013 · AR · contact PI
Targeting Adiponectin Signaling: Novel Peptide Therapy for Scleroderma$207,521
R21 · FY2013 · AR · contact PI
Molecular Basis of Fibrosis: Regulation of Collagen$142,479
R01 · FY2013 · AR · contact PI
Core D - Proteomic and Clinical Core$138,610
P30 · FY2013 · AR · contact PI
Molecular Basis of Fibrosis: Regulation of Collagen$331,717
R01 · FY2012 · AR · contact PI
Fibroblast TGF-beta/Signaling in Scleroderma: Modulation by PPAR-gamma$315,723
R01 · FY2012 · AR · contact PI
Core D - Proteomic and Clinical Core$145,906
P30 · FY2012 · AR · contact PI
Molecular Basis of Fibrosis: Regulation of Collagen$331,627
R01 · FY2011 · AR · contact PI
Fibroblast TGF-beta/Signaling in Scleroderma: Modulation by PPAR-gamma$319,471
R01 · FY2011 · AR · contact PI
Core D - Proteomic and Clinical Core$167,750
P30 · FY2011 · AR · contact PI
Molecular Basis of Fibrosis: Regulation of Collagen$357,169
R01 · FY2010 · AR · contact PI
Fibroblast TGF-beta/Signaling in Scleroderma: Modulation by PPAR-gamma$332,781
R01 · FY2010 · AR · contact PI
Fibroblast TGF-beta/Signaling in Scleroderma: Modulation by PPAR-gamma$457,500
R01 · FY2009 · AR · contact PI
Fibroblast TGF-beta/Signaling in Scleroderma: Modulation by PPAR-gamma$349,551
R01 · FY2009 · AR · contact PI
Fibroblast TGF-beta/Signaling in Scleroderma: Modulation by PPAR-gamma$348,571
R01 · FY2008 · AR · contact PI
MOLECULAR BASIS: REGULATION OF COLLAGEN BY TGF-BETA$301,322
R01 · FY2008 · AR · contact PI
MOLECULAR BASIS: REGULATION OF COLLAGEN BY TGF-BETA$307,472
R01 · FY2007 · AR · contact PI
MOLECULAR BASIS: REGULATION OF COLLAGEN BY TGF-BETA$316,655
R01 · FY2006 · AR · contact PI
Fibroblast TGF-beta/Smad Signaling in Scleroderma$292,015
R01 · FY2006 · AR · contact PI
MOLECULAR BASIS: REGULATION OF COLLAGEN BY TGF-BETA$324,276
R01 · FY2005 · AR
Fibroblast TGF-beta/Smad Signaling in Scleroderma$299,042
R01 · FY2005 · AR
MOLECULAR BASIS: REGULATION OF COLLAGEN BY TGF-BETA$216,906
R01 · FY2004 · AR
Fibroblast TGF-beta/Smad Signaling in Scleroderma$190,216
R01 · FY2004 · AR
Fibroblast TGF-beta/Smad Signaling in Scleroderma$142,879
R01 · FY2004 · AR
MOLECULAR BASIS: REGULATION OF COLLAGEN BY TGF-BETA$112,627
R01 · FY2004 · AR
Fibroblast TGF-beta/Smad Signaling in Scleroderma$340,186
R01 · FY2003 · AR
REGULATION OF COLLAGEN GENE EXPRESSION BY TGF BETA$249,564
R01 · FY2003 · AR
Fibroblast TGF-beta/Smad Signaling in Scleroderma$340,186
R01 · FY2002 · AR
REGULATION OF COLLAGEN GENE EXPRESSION BY TGF BETA$245,281
R01 · FY2002 · AR
IDO: A Novel Endogenous Suppressor of Inflammation$77,935
R21 · FY2002 · AR
REGULATION OF COLLAGEN GENE EXPRESSION BY TGF BETA$241,114
R01 · FY2001 · AR
IDO: A Novel Endogenous Suppressor of Inflammation$77,935
R21 · FY2001 · AR
REGULATION OF COLLAGEN GENE EXPRESSION BY TGF BETA$236,587
R01 · FY2000 · AR